JNJ-32729463

DRUG2 trials

Sponsors

Furiex Pharmaceuticals, Inc

Conditions

Community-Acquired Bacterial Pneumonia (CABP)Complicated Skin and Skin Structure Infections

Phase 2

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

CompletedNCT01128530

Furiex Pharmaceuticals, IncComplicated Skin and Skin Structure Infections

Start: 2010-06-30End: 2011-01-31Updated: 2011-12-16

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

TerminatedNCT01198626

Furiex Pharmaceuticals, IncCommunity-Acquired Bacterial Pneumonia (CABP)

Start: 2010-10-31End: 2011-10-31Updated: 2011-12-08